Escin IA

Synonyms: 七叶皂苷A
Escin IA 是一种口服 LOXL2 抑制剂和 EMT 抑制剂,对表达 LOXL2 的细胞具有选择性,可抑制乳腺癌细胞的侵袭、迁移和转移,是七叶树(Aesculus chinensis Bunge)果实皂苷组分中发挥抗三阴性乳腺癌(TNBC)转移作用的主要成分,可用于三阴性乳腺癌、急性炎症及乙醇诱导的胃黏膜损伤相关研究。
产品编号: MS-J26795 纯度: 99.59% CAS No.: 123748-68-5 分子式: C55H86O24 分子量: 1131.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Escin IA 是一种口服 LOXL2 抑制剂和 EMT 抑制剂,对表达 LOXL2 的细胞具有选择性,可抑制乳腺癌细胞的侵袭、迁移和转移,是七叶树(Aesculus chinensis Bunge)果实皂苷组分中发挥抗三阴性乳腺癌(TNBC)转移作用的主要成分,可用于三阴性乳腺癌、急性炎症及乙醇诱导的胃黏膜损伤相关研究。

生物实验数据

生物活性 Escin IA is an orally active LOXL2 inhibitor and EMT inhibitor that is selective for LOXL2-expressing cells, inhibits the invasion, migration, and metastasis of breast cancer cells, and is the main component responsible for the anti-triple-negative breast cancer (TNBC) metastasis effect of the saponin fraction from the fruit of Aesculus chinensis Bunge, making it useful for research on triple-negative breast cancer, acute inflammation, and ethanol-induced gastric mucosal injury.
IC50 & Target HIV-1 protease:35 μM
体外研究
(In Vitro)

Escin Ia (2.5-10 μM;24 h) 以浓度依赖的方式抑制 MDA-MB-231 细胞的侵袭,其中 10 μM 浓度下的抑制作用最强 (76.23%)。
Escin Ia (2.5-10 μM; 24 h) 可调控 MDA-MB-231 细胞中LOXL2、E-钙粘蛋白 (E-cadherin)和MMP9的 mRNA 表达,其中LOXL2表达下调与E-钙粘蛋白 (E-cadherin)表达上调为其显著作用。
Escin Ia (2.5-10 μM; 6-24 h, unspecified intervals) 可通过调控上皮间质转化 (EMT) 标志物及转录因子,抑制 MDA-MB-231 细胞中的上皮间质转化 (EMT) 过程。
Escin Ia (2.5-10 μM;6-24 h, unspecified intervals) 可通过使 EMT 标志物表达恢复正常,逆转经 TNF−α/TGF−β刺激的 MCF-7 细胞中的 EMT 进程。
Escin Ia (2.5-10 μM;6-24 h,unspecified intervals) 可下调 MDA-MB-231 细胞中 LOXL2 的表达,并可消除经 TNF-α/TGF-β 刺激或转染 LOXL2 的 MCF-7 细胞中诱导产生的 LOXL2 表达。
Escin Ia (2.5-10 μM; unspecified intervals) 可通过下调 LOXL2 表达并使 EMT 标记物恢复正常,来抑制转染 LOXL2 的 MCF-7 细胞中的 EMT 进程。
Escin Ia (2.5-10 μM; unspecified intervals) 可通过下调 LOXL2 (不影响 HIF-1α) 并使 EMT 标志物恢复正常,从而抑制低氧诱导的 MCF-7 细胞中的 EMT 进程。

Cell Invasion Assay

Cell Line: MDA-MB-231
Concentration: 5 μM; 2.5-10 μM
Incubation Time: 24 h
Result: Inhibited MDA-MB-231 cell invasion by 68.92% at 5 μM (stronger than other escin analogs); inhibited invasion by 39.46% at 2.5 μM, 64.22% at 5 μM, and 76.23% at 10 μM.

Real Time qPCR

Cell Line: MDA-MB-231
Concentration: 2.5-10 μM
Incubation Time: 24 h
Result: Down-regulated LOXL2 mRNA expression and up-regulated E-cadherin mRNA expression; moderately down-regulated MMP9 mRNA expression at 10 μM; exerted slight effects on BRMS1, Keratin19, Orai1, Stim1, TGF-β, and VEGF mRNAs.
体内研究
(In Vivo)

Escin Ia (2-4 mg/kg; i.p.; three times per week; five weeks) 通过下调 LOXL2 抑制 MDA-MB-231 异种移植小鼠的 TNBC 转移和 EMT,且 4 mg/kg 剂量的疗效优于 2 mg/kg。
Escin Ia (50-200 mg/kg; p.o.) 可剂量依赖性地抑制醋酸诱导的Mus musculus血管通透性,在 200 mg/kg 剂量下的抑制率为 43.6%。
Escin Ia (25-200 mg/kg; p.o.) 可抑制 compound 48/80 诱导的小鼠搔抓行为,在 200 mg/kg 剂量下的抑制率达 42.4%,具有统计学显著性。
Escin Ia (200 mg/kg; p.o.) 可显著抑制角叉菜胶诱导的大鼠爪水肿早期阶段 (1 hour)。
Escin Ia (25-200 mg/kg; p.o.) 可呈剂量依赖性抑制大鼠体内组胺诱导的血管通透性 (在 50-200 mg/kg 剂量下具有显著性),但不抑制 5-羟色胺诱导的血管通透性。
Escin IA (10-50 mg/kg; p.o.; single dose 1 hour before ethanol administration) 可通过涉及辣椒素敏感传入神经元、内源性一氧化氮和前列腺素的机制,强效保护大鼠免受乙醇诱导的胃黏膜损伤,且在有效剂量下无胃酸分泌抑制活性。
Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃保护作用依赖于辣椒素敏感的传入神经元。
Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 其在大鼠体内的胃保护作用依赖于内源性前列腺素。
Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 的胃黏膜保护作用依赖于大鼠体内的内源性一氧化氮。
Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃黏膜保护作用不依赖内源性巯基。
Escin IA (10-20 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃保护作用依赖于交感神经系统。

Animal Model: athymic nude mice (female, 4-6 week-old)
Dosage: 2 mg/kg; 4 mg/kg
Administration: i.p.; three times per week; five weeks
Result: Down-regulated LOXL2, vimentin, α-SMA, Snail, Slug, Zeb1, Zeb2, and Twist, and up-regulated E-cadherin at protein and mRNA levels in breast tumors (4 mg/kg); showed little effect on HIF-1α expression in breast tumors (2 mg/kg, 4 mg/kg)
Animal Model: ddY mice (male, 27-30 g, acetic acid-induced vascular permeability model)
Dosage: 50, 100, 200 mg/kg
Administration: p.o.
Result: Inhibited acetic acid-induced vascular permeability with 12.1% inhibition at 50 mg/kg, 30.6% inhibition at 100 mg/kg, and 43.6% inhibition at 200 mg/kg.
Animal Model: ddY mice (male, 26-29 g, compound 48/80-induced scratching model)
Dosage: 25, 50, 100, 200 mg/kg
Administration: p.o.
Result: Inhibited compound 48/80-induced scratching with 16.8% inhibition at 25 mg/kg, 32.4% inhibition at 50 mg/kg, 31.5% inhibition at 100 mg/kg, and 42.4% inhibition at 200 mg/kg (significant at 200 mg/kg).
Animal Model: Wistar rats (male, 140-160 g, carrageenin-induced hind paw edema model)
Dosage: 200 mg/kg
Administration: p.o.
Result: Significantly inhibited carrageenin-induced hind paw swelling at 1 hour but showed no effect at 3-5 hours.
Animal Model: Wistar rats (male, 140-150 g, histamine/serotonin-induced vascular permeability model)
Dosage: 25, 50, 100, 200 mg/kg
Administration: p.o.
Result: Inhibited histamine-induced vascular permeability with significant effects at 50 mg/kg (28.4 μg/site dye leakage), 100 mg/kg (28.5 μg/site), and 200 mg/kg (19.4 μg/site); did not significantly inhibit serotonin-induced vascular permeability at any dose.
Animal Model: Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; ethanol-induced gastric mucosal lesions)
Dosage: 10, 20, 50 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Dose-dependently reduced ethanol-induced gastric lesion scores; showed potent protective effect at 10-50 mg/kg. Did not decrease gastric secretion (volume, acid output, pepsin output) in pylorus-ligated rats at 10 and 20 mg/kg. Had gastroprotective effect attenuated by pretreatment with capsaicin, indomethacin, or L-NAME at 10 mg/kg. Had gastroprotective effect not attenuated by pretreatment with N-ethylmaleimide at 10 mg/kg. Showed marked attenuation of gastroprotective effect in streptozotocin-induced diabetic rats at 10 and 20 mg/kg.
Animal Model: Sprague-Dawley (male, 180-200 g for capsaicin pretreatment; 250 g for other pretreatments, fasted 24-26 hours prior to experiments; capsaicin-pretreated, ethanol-induced gastric mucosal lesions)
Dosage: 10 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Showed gastroprotective effect against ethanol-induced lesions markedly attenuated by capsaicin pretreatment.
Animal Model: Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; indomethacin-pretreated, ethanol-induced gastric mucosal lesions)
Dosage: 10 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Showed gastroprotective effect against ethanol-induced lesions partly reduced by indomethacin pretreatment.
Animal Model: Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; L-NAME-pretreated, ethanol-induced gastric mucosal lesions)
Dosage: 10 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Showed gastroprotective effect against ethanol-induced lesions partly reduced by L-NAME pretreatment.
Animal Model: Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; N-ethylmaleimide-pretreated, ethanol-induced gastric mucosal lesions)
Dosage: 10 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Showed gastroprotective effect against ethanol-induced lesions not attenuated by N-ethylmaleimide pretreatment.
Animal Model: Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; streptozotocin-induced diabetic, ethanol-induced gastric mucosal lesions)
Dosage: 10, 20 mg/kg
Administration: p.o.; single dose 1 hour before ethanol administration
Result: Showed marked attenuation of gastroprotective effect against ethanol-induced lesions in streptozotocin-induced diabetic rats at 10 and 20 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 1131.26
分子式 C55H86O24
CAS No. 123748-68-5
别名 七叶皂苷A

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.77 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (88.40 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.8840 mL4.4199 mL8.8397 mL22.0993 mL
5 mM0.1768 mL0.8840 mL1.7679 mL4.4199 mL
10 mM0.0884 mL0.4420 mL0.8840 mL2.2099 mL
15 mM0.0589 mL0.2947 mL0.5893 mL1.4733 mL
20 mM0.0442 mL0.2210 mL0.4420 mL1.1050 mL
25 mM0.0354 mL0.1768 mL0.3536 mL0.8840 mL
30 mM0.0295 mL0.1473 mL0.2947 mL0.7366 mL
40 mM0.0221 mL0.1105 mL0.2210 mL0.5525 mL
50 mM0.0177 mL0.0884 mL0.1768 mL0.4420 mL
60 mM0.0147 mL0.0737 mL0.1473 mL0.3683 mL
80 mM0.0110 mL0.0552 mL0.1105 mL0.2762 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础